Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 2, 2013, Pages 366-369

  Gonzalo, Ximena ^a   Drobniewski, Francis ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

; lactamases; MDR XDR TB; Mycobacterium tuberculosis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ISONIAZID; MEROPENEM; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; DRUG DETERMINATION; DRUG POTENTIATION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; IN VITRO STUDY; MULTIDRUG RESISTANCE;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CLAVULANIC ACID; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; THIENAMYCINS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84872419352     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks395     Document Type: Article

References (10)

1. Lawn SD, Zumla AI. Tuberculosis. Lancet 2011; 378: 57-72.
2. Falzon D, Jaramillo E, Schunemann HJ et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-28.
3. Wong CS, Palmer GS, Cynamon MH. In-vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium kansasii to amoxycillin and ticarcillin in combination with clavulanic acid. J Antimicrob Chemother 1988; 22: 863-6.
4. Hugonnet JE, Tremblay LW, Boshoff HI et al. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009; 323: 1215-8.
5. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary. 62nd edn. London, UK: BMJ Publishing Group, 2011.
6. Conte JE Jr., Golden JA, Kelley MG et al. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem. Int J Antimicrob Agents 2005; 26: 449-56.
7. Chambers HF, Kocagoz T, Sipit T et al. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin Infect Dis 1998; 26: 874-7.
8. White AR, Kaye C, Poupard J et al. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004; 53 Suppl 1: i3-20.
9. Payen MC, De Wit S, Martin C et al. Clinical use of the meropenem/ clavulanate combination for extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 2012; 16: 558-60.
10. Laszlo A, Rahman M, Raviglione M et al. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/ IUATLD Supranational Laboratory Network: first round of proficiency testing. Int J Tuberc Lung Dis 1997; 1: 231-8.